David Blaine Ridley

Associate Professor of the Practice of Business Administration

External Address: 
100 Fuqua Drive, Durham, NC 27708-0120
Internal Office Address: 
Duke Box 90120, 100 Fuqua Drive, Durham, NC 27708-0120
(919) 660-3784

David Ridley is the Dr. and Mrs. Frank A. Riddick Associate Professor of the Practice of Business and Economics. He is also the Faculty Director of the Health Sector Management program at Duke University's Fuqua School of Business. In his research, David examines life sciences innovation and pricing. David was the lead author of a paper proposing the priority review voucher program to encourage development of drugs and vaccines for neglected diseases. It became law in the U.S. in 2007.


  • Ph.D., Duke University 2001
  • M.A., Duke University 1995
  • B.A., University of Missouri at Columbia 1993

Ridley, DB. "Hotelling’s Law." In Palgrave Encyclopedia of Strategic Management,edited by D Teece and M Augier. 2013.

Towse, A, Keuffel, E, Kettler, HE, and Ridley, DB. "Drugs and Vaccines for Developing Countries." In The Oxford Handbook of the Economics of the Biopharmaceutical Industry. September 18, 2012. Full Text

Grabowski, HG, Ridley, David B., , Moe, and Jeffrey L., . "Encouraging innovative treatment of neglected diseases through priority review vouchers." In Prescribing Cultures and Pharmaceutical Policy in the Asia-Pacific,edited by K Eggleston,347-365. Stanford, CA: Stanford University: The Walter H, Shorenstein Asia-Pacific Research Center, September 1, 2009. Open Access Copy

Ridley, DB, and Zhang, S. "Regulation of price increases." International Journal of Industrial Organization 50 (January 2017): 186-213. Full Text

Ridley, DB, and Régnier, SA. "The Commercial Market For Priority Review Vouchers." Health affairs (Project Hope) 35, no. 5 (May 2016): 776-783. Full Text

Ridley, DB, Dent, J, and Egerton-Warburton, C. "Efficacy of the Priority Review Voucher Program." JAMA 315, no. 15 (April 2016): 1659-1660. (Letter) Full Text

Ridley, DB, Bei, X, and Liebman, EB. "No Shot: US Vaccine Prices And Shortages." Health affairs (Project Hope) 35, no. 2 (February 2016): 235-241. Full Text

Regnier, SA, and Ridley, DB. "Market watch: Forecasting market share in the US pharmaceutical market." Nature reviews. Drug discovery 14, no. 9 (September 2015): 594-595. Full Text

Ridley, DB. "Payments, promotion, and the purple pill." Health Economics (United Kingdom) 24, no. 1 (January 1, 2015): 86-103. Full Text

Arcidiacono, P, Ellickson, PB, Landry, P, and Ridley, DB. "Pharmaceutical followers." International Journal of Industrial Organization 31, no. 5 (November 15, 2013): 538-553. Full Text

Gans, JS, and Ridley, DB. "Innovation incentives under transferable fast-track regulatory review." Journal of Industrial Economics 61, no. 3 (September 1, 2013): 789-816. Full Text

Ridley, DB. "Payments, promotion, and the purple pill (Accepted)." Health Economics (United Kingdom) (2013). Full Text

Ridley, DB, and Sánchez, AC. "Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases." Lancet 376, no. 9744 (September 11, 2010): 922-927. Full Text


GHTC R&D Mapping awarded by PATH (Principal Investigator). 2016 to 2017

Determinants and Consequences of Alcohol Consumption awarded by National Institutes of Health (Investigator). 2005 to 2011